查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2153399

2026-2034年全球急性偏頭痛治療市場規模、佔有率、趨勢和成長分析報告

Global Acute Migraine Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球急性偏頭痛治療市場預計將從2025年的48億美元成長至2034年的176.4億美元，2026年至2034年的複合年成長率（CAGR）為15.57%。受全球偏頭痛盛行率上升的推動，全球急性偏頭痛治療市場呈現強勁成長動能。壓力水平的增加、生活方式的改變以及人們對神經系統健康的日益關注，都促進了偏頭痛診斷率的提高。市場對快速有效的治療方法（例如曲坦類藥物和CGRP拮抗劑）的需求不斷成長。藥物技術的進步以及對偏頭痛病理生理學的深入了解，正在進一步加速市場發展。

關鍵成長要素包括醫療服務可近性的提高、神經系統研究投入的增加以及新療法的推出。工作年齡人口中慢性偏頭痛負擔日益加重，推動了對先進治療方案的需求。此外，患者對非侵入性和標靶療法的偏好也促進了產品創新。新一代藥物的法規核准和宣傳宣傳活動的擴大也有助於提高全球藥物普及率。

受持續藥物研發和生物製藥療法推廣的推動，市場前景依然強勁。個人化醫療方法和數位化健康監測工具可望提升治療效果。新興市場醫療保險覆蓋範圍的擴大將開闢新的成長途徑。隨著研發的不斷深入和創新產品的不斷湧現，急性偏頭痛治療市場預計將在長期內保持持續成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球急性偏頭痛治療市場：依藥物類型分類

  • 市場分析、洞察與預測
  • 曲坦類藥物
  • CGRP拮抗劑
  • 非類固醇抗發炎藥
  • BETA-腎上腺素受體阻斷劑
  • 麥角生物鹼
  • 其他

第5章：全球急性偏頭痛治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 注射
  • 其他

第6章 全球急性偏頭痛治療市場：依通路分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章 全球急性偏頭痛治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • AbbVie
    • Pfizer
    • Eli Lilly
    • Teva Pharmaceuticals
    • Amgen
    • Lundbeck
    • Viatris
    • Sandoz
    • Dr. Reddy's Laboratories
    • Sun Pharma
    • Zydus Lifesciences
    • Cipla
    • Bausch Health
    • Axsome Therapeutics
    • Biohaven
    • Impax Laboratories
    • Assertio Therapeutics
    • Collegium Pharmaceutical
    • Tonix Pharmaceuticals
    • BioDelivery Sciences
簡介目錄
Product Code: VMR112110233

The global acute migraine treatment market size is expected to reach USD 17.64 Billion in 2034 from USD 4.80 Billion in 2025, growing at a CAGR of 15.57% during 2026-2034.The Global Acute Migraine Treatment Market is witnessing robust growth driven by rising prevalence of migraine disorders worldwide. Increasing stress levels, lifestyle changes, and neurological health awareness are contributing to higher diagnosis rates. Demand for fast-acting and effective treatment options, including triptans and CGRP antagonists, is expanding. Pharmaceutical advancements and improved understanding of migraine pathophysiology are further accelerating market development.

Key growth drivers include increasing healthcare access, rising investment in neurological research, and the introduction of novel therapeutics. The growing burden of chronic migraine among working-age populations is encouraging demand for advanced treatment solutions. Additionally, patient preference for non-invasive and targeted therapies is shaping product innovation. Regulatory approvals of next-generation drugs and increasing awareness campaigns are also boosting adoption rates globally.

Future prospects remain strong with continued drug development and expansion of biologic therapies. Personalized medicine approaches and digital health monitoring tools are expected to enhance treatment outcomes. Expanding healthcare coverage in emerging markets will create new growth avenues. With ongoing research and pipeline innovations, the acute migraine treatment market is poised for sustained long-term expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug Type

  • Triptans
  • CGRP Antagonist
  • NSAID Drugs
  • Beta-Adrenergic Blockers
  • Ergot Alkaloids
  • Others

By Route of Administration

  • Oral
  • Injection
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • AbbVie, Pfizer, Eli Lilly, Teva Pharmaceuticals, Amgen, Lundbeck, Viatris, Sandoz, Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Cipla, Bausch Health, Axsome Therapeutics, Biohaven, Impax Laboratories, Assertio Therapeutics, Collegium Pharmaceutical, Tonix Pharmaceuticals, BioDelivery Sciences

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ACUTE MIGRAINE TREATMENT MARKET: BY DRUG TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Type
  • 4.2. Triptans Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. CGRP Antagonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. NSAID Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Beta-Adrenergic Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Ergot Alkaloids Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ACUTE MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Route Of Administration
  • 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ACUTE MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Distribution Channel
  • 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ACUTE MIGRAINE TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Drug Type
    • 7.2.2 By Route Of Administration
    • 7.2.3 By Distribution Channel
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Drug Type
    • 7.3.2 By Route Of Administration
    • 7.3.3 By Distribution Channel
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Spain
    • 7.3.9 Russia
    • 7.3.10 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Drug Type
    • 7.4.2 By Route Of Administration
    • 7.4.3 By Distribution Channel
    • 7.4.4 China
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 India
    • 7.4.8 Australia
    • 7.4.9 South East Asia
    • 7.4.10 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Drug Type
    • 7.5.2 By Route Of Administration
    • 7.5.3 By Distribution Channel
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Drug Type
    • 7.6.2 By Route Of Administration
    • 7.6.3 By Distribution Channel
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ACUTE MIGRAINE TREATMENT INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 AbbVie
    • 9.2.2 Pfizer
    • 9.2.3 Eli Lilly
    • 9.2.4 Teva Pharmaceuticals
    • 9.2.5 Amgen
    • 9.2.6 Lundbeck
    • 9.2.7 Viatris
    • 9.2.8 Sandoz
    • 9.2.9 Dr. Reddy's Laboratories
    • 9.2.10 Sun Pharma
    • 9.2.11 Zydus Lifesciences
    • 9.2.12 Cipla
    • 9.2.13 Bausch Health
    • 9.2.14 Axsome Therapeutics
    • 9.2.15 Biohaven
    • 9.2.16 Impax Laboratories
    • 9.2.17 Assertio Therapeutics
    • 9.2.18 Collegium Pharmaceutical
    • 9.2.19 Tonix Pharmaceuticals
    • 9.2.20 BioDelivery Sciences